Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.

Charbonnier, B A; Fiessinger, J N; Banga, J D; Wenzel, E; d'Azemar, P; Sagnard, L

Charbonnier, B A; Fiessinger, J N; Banga, J D; Wenzel, E; d'Azemar, P; Sagnard, L.

Affiliation

Charbonnier BA; University Hospital Trousseau, Tours, France.

Thromb Haemost ; 79(5): 897-901, 1998 May.

Article in En | MEDLINE | ID: mdl-9609216

Subject(s)

Anticoagulants/administration & dosage; Nadroparin/administration & dosage; Thrombophlebitis/drug therapy; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants/adverse effects; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Nadroparin/adverse effects; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Thrombophlebitis / Nadroparin / Anticoagulants Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Thromb Haemost Year: 1998 Type: Article Affiliation country: France

Search on Google

Add to My VHL

XML

PubMed Links